[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malnutrition\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malnutrition":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,60,0,25,[9,47,74,99,124,150,181,205,231,275,298,331,359,394,428,450,471,498,526,554,584,608,637,660,691],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100326360","early-phase-1-nutrition-in-patient-with-critical-limb-ischemia-100326360",false,"NCT03529019","Nutrition in Patient With Critical Limb Ischemia","Perioperative Nutritional Optimization in Patients With Critical Limb Ischemia","NutriVasc","Inclusion Criteria:\n\n* Critical Limb Ischemia\n\nExclusion Criteria:\n\n* Female patients who are pregnant or lactating\n* Chronic Kidney Disease Stages 4 and 5\n* Patients who are on dialysis","ALL","18 Years","99 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"EARLY_PHASE1","A prospective pilot study examining nutritional supplements among vascular surgery patients with Critical Limb Ischemia (CLI). CLI patients have a high rate of malnutrition and has the potential to benefit greatly from nutritional intervention. The investigators plan to evaluate nutrition and functional status of patients by assessing objective lab values and the use of the hand grip strength test. Providing perioperative nutritional supplements to patients has potentially improved their nutritional status, which in turn may improve the patient's clinical status after surgery.",[29,30,31],"Critical Limb Ischemia","Malnutrition","Nutritional Supplements",[33],"Enhanced Recovery After Surgery Protocol","RECRUITING","2026-06-29",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":38},"2018-10-02",{"date":42,"type":23},"2026-09",{"name":44,"class":45},"Boston Medical Center","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100644691","gastrointestinal-hormones-and-metabolomic-profiling-following-mixed-meal-tolerance-tests-in-patients-at-risk-of-refeeding-syndrome-100644691","NCT07674589","Gastrointestinal Hormones and Metabolomic Profiling Following Mixed-Meal Tolerance Tests in Patients at Risk of Refeeding Syndrome","Combined Assessment of Gastrointestinal Hormones and Metabolomic Profiling Following Mixed-Meal Tolerance Tests in Patients at High Risk of Refeeding Syndrome: Study Protocol","Inclusion Criteria:\n\n* Age above 18 years.\n* Oral ingestion below 50% of energy daily needs for ≥ 1 month.\n* Absence of artificial nutrition before PEG placement.\n\nExclusion Criteria:\n\n* Age below 18 years.\n* Quantified food ingestion above 50% of energy daily needs during the last month.\n* Oncologic disease.\n* Diabetes mellitus.\n* Expected survival below 3 months.\n* Inability to provide credible anamnestic data.\n* Impossibility to have an appropriate clinical and nutritional follow-up.",{"count":55,"type":23},15,"OBSERVATIONAL","Introduction: Refeeding syndrome (RS) is a life-threatening metabolic complication of nutritional support. Prolonged fasting, frequently observed in malnourished patients referred for percutaneous endoscopic gastrostomy (PEG), induces histological and ultrastructural changes in the intestinal mucosa, potentially influencing RS development. Mixed-Meal Tolerance Tests (MMTT) combined with metabolomics allow dynamic assessment of serum glucose, gastrointestinal hormones and cellular metabolites, which may help to elucidate RS pathogenesis and assess patient risk. Objective: The present study aims to perform MMTT in PEG-fed patients to evaluate enteroendocrine hormone responses and metabolomic profiles following a prolonged fasting period and subsequent enteral refeeding. Methods: This prospective, single-center study includes adults referred for PEG after at least one month of oral intake below 50% of energy needs. The MMTT will be performed at PEG placement and after 3-6 months of enteral nutrition. Serial blood samples will be collected from baseline up to 120 minutes post-meal to measure serum glucose, insulin, C-peptide, electrolytes and gastrointestinal hormones (GLP-1\u002FGIP\u002FGhrelin\u002FPeptide YY), and for metabolomic profiling by spectroscopy. Clinical and nutritional data will be prospectively recorded. Statistical and multivariate analyses will assess metabolic and hormonal changes over time and their potential association with patient refeeding syndrome risk and clinical outcome. The study was approved by the institutional ethics committee, and patient informed consent will be obtained. Conclusion: This study integrates MMTT and metabolomic profiling to characterize hormonal and metabolic responses during fasting and refeeding in high-risk PEG patients. Findings are expected to reveal underlying mechanisms of RS, identify potential predictive biomarkers, and improve individualized risk stratification and nutritional management.",[59,30],"Refeeding Syndrome",[59,61,62,63,64],"Gastrointestinal Hormones","Metabolomics","Mixed-Meal Tolerance Tests","PEG","NOT_YET_RECRUITING","2026-06-25",{"date":35,"type":38},{"date":69,"type":23},"2026-07",{"date":71,"type":23},"2027-07",{"name":73,"class":45},"Hospital Garcia de Orta",{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":46},"100433358","impact-of-auditory-stimulation-in-eating-pleasure-edere-2021-100433358","NCT04923087","Impact of Auditory Stimulation in Eating Pleasure (EDERE 2021)","Impact of Auditory Stimulation in Eating Pleasure : Multicentric Study With Biscuits With Crunchy Texture vs Soft Texture in 100 Seniors Affected or at Risk of Presbyacusis","EDERE 2021","Inclusion Criteria:\n\nSubjects 65 years of age or older, hospitalized in geriatrics or EHPAD residents.\n\nExclusion Criteria:\n\nrisk of false route when eating cookies, allergy to an ingredient in cookies",true,"65 Years",{"count":85,"type":23},100,"Background. Decreased taste and smell contribute to loss of appetite (anorexia), and the resulting protein-energy malnutrition increases the frailty of the elderly. The risk of falls, disability, infections and depression often requires them to be institutionalized. Elderly, undernourished and toothless patients often complain about the monotony of a soft, mixed-texture diet. In a previous study, some participants highlighted the pleasure of crunching cookies that have a solid texture that can be eaten in any dental condition. However, the age-related decrease in hearing (presbyacusis) is frequent and progressive from the age of 60. The hypothesis of this work is that older patients may perceive a crunchy food crunching in their mouth, despite presbycusis. If the hypothesis is verified, this would make geriatric caregivers aware of the possibility of diversifying the texture of food, in order to stimulate the pleasure of eating and increase the dietary intake in this population of patients who are often undernourished, dysphagic, edentulous and hearing impaired. The originality of this study is to share the expertise of geriatricians and specialists in mastication\u002Fswallowing (dental surgeon, speech-language pathologist), hearing (ENT doctor, hearing care professional) and nutrition (dietician).\n\nType of study. Type of study MR-004 \"Research not involving the human person\". Protocol. Compare the noise and pleasure of crunching between two hyperprotein nutritional supplements: a soft filled cookie (Nutra Cake™, Délical, France) and a crunchy cookie of the Breton type (Protibis™, Solidages, France). Blind study impossible: each subject will eat a cookie then the other in a random order and will be his own control. The tests will be performed without the possible hearing aids, but with or without the dentures according to the patient's preference. Indeed, some patients have dental prostheses that are no longer suitable for chewing, and that they wear only for aesthetics. Objective. Validate the evaluation criteria \"Do you hear the biscuit crunch?\" and \"Is it a pleasure?\" If so, encourage diversification with crunchy foods with a suitable texture, as well as dental and prosthetic rehabilitation of dependent elderly people.",[88,30,89,90,91],"Frailty","Anorexia","Presbycusis","Edentulism Nos",{"date":35,"type":38},{"date":94,"type":38},"2021-06-01",{"date":96,"type":23},"2027-06-25",{"name":98,"class":45},"Centre Hospitalier Universitaire de Nice",{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":46},"100628570","preoperative-oral-nutrition-and-outcomes-in-frail-elderly-patients-with-femur-fractures-100628570","NCT07463352","Preoperative Oral Nutrition And Outcomes In Frail Elderly Patients With Femur Fractures","Evaluation of the Effects of Preoperative Oral Nutritional Support on Hemodynamic Stability, Morbidity, Mortality, and Anthropometric Measurements in Patients With Femur Fractures and High Frailty Index: A Prospective Observational Study","Inclusion Criteria:\n\n* Patients aged 65 years or older hospitalized with a diagnosis of femur fracture\n* High frailty index (Clinical Frailty Scale ≥ 5)\n* Patients expected to require postoperative intensive care\n\nExclusion Criteria:\n\n* Patients requiring preoperative intensive care\n* Patients unable to tolerate enteral nutrition\n* Patients with advanced liver or kidney failure\n* Patients unable to cooperate\n* Patients with neuromuscular disease\n* Patients with severe malnutrition according to NRS-2002 guidelines\n* Patients who refuse to participate",{"count":107,"type":23},228,"The goal of this observational study is to learn whether preoperative oral nutrition support improves clinical outcomes in elderly patients with femur fractures who have a high frailty index. The main questions it aims to answer are:\n\n* Does preoperative nutrition support improve hemodynamic stability during and after surgery?\n* Does it reduce postoperative complications, mortality, and length of hospital stay?\n\nResearchers will compare patients who receive preoperative oral nutrition support with those who follow routine nutrition.\n\nParticipants will:\n\n* Receive routine medical care with or without nutrition support\n* Have their hemodynamic values, complications, and outcomes recorded during hospitalization\n* Be followed at 30 and 90 days after surgery for complications and mortality.",[110,88,30],"Femoral Fractures",[112,113,88,30,114],"Hip Fractures","Geriatric Patients","Hemodynamic Stability","2026-06-15",{"date":117,"type":38},"2026-06-16",{"date":119,"type":38},"2026-03-12",{"date":121,"type":23},"2027-01-01",{"name":123,"class":45},"Duzce University",{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":46},"100640485","postoperative-gi-dysfunction-and-nutrition-in-malnourished-cancer-surgery-patients-100640485","NCT07622888","Postoperative GI Dysfunction and Nutrition in Malnourished Cancer Surgery Patients","Gastrointestinal Dysfunction, Nutritional Status, and Delirium in the Early Postoperative Period in Oncologic Surgical Patients With Pre-existing Malnutrition: A Prospective Two-Center Observational Cohort Study","GIDNUT","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically confirmed malignant tumor of the abdomen or pelvis with planned radical or cytoreductive surgery.\n* Baseline malnutrition defined as NRS2002 ≥ 3 and at least one phenotypic and one etiologic GLIM criterion.\n* Expected postoperative hospitalization ≥ 7 days.\n* Ability to undergo baseline cognitive and nutritional assessments (MoCA, NRS2002, GLIM, PG-SGA) prior to surgery.\n* Signed informed consent for participation and data collection.\n\nExclusion Criteria:\n\n* Severe decompensated hepatic or renal failure rendering surgery infeasible.\n* Documented preexisting severe cognitive impairment or dementia precluding valid postoperative cognitive\u002Fdelirium assessment (e.g., MoCA \\\u003C 18 or documented dementia).\n* Pregnancy or breastfeeding.\n* Participation in another interventional randomized clinical trial within the prior 30 days that could confound outcomes.\n* Inability to ensure postoperative follow-up or reliable data collection (planned transfer without access, loss of contact).",{"count":133,"type":23},120,"This is a prospective two-center observational cohort study in adult patients undergoing major abdominal and\u002For pelvic oncologic surgery with pre-existing malnutrition. The study describes the course of postoperative gastrointestinal dysfunction and evaluates whether real-world exposure to parenteral serotonin as part of routine postoperative care is associated with a higher proportion of patients whose gastrointestinal dysfunction regresses to LIFE score less than or equal to 1 by postoperative day 5 (plus or minus 1 day), compared with patients not exposed to serotonin.\n\nAll treatment decisions, including the use of parenteral serotonin, metoclopramide, neostigmine, nutritional support, and other postoperative management, are made solely by the treating physicians in accordance with routine clinical practice. The protocol does not assign, randomize, require, or restrict any drug treatment; it records real-world care, daily LIFE assessments during postoperative days 1 through 7, nutritional status measures, body composition where available, delirium screening, complications, length of stay, and mortality.",[136,30,137,138,139],"Gastrointestinal Dysfunction","Delirium - Postoperative","Abdominal Neoplasm","Pelvic Neoplasm","2026-05-31",{"date":142,"type":38},"2026-06-03",{"date":144,"type":23},"2026-10-01",{"date":146,"type":23},"2029-03-01",{"name":148,"class":149},"Arma Ltd.","INDUSTRY",{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":24,"phases":158,"briefSummary":160,"conditions":161,"keywords":166,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":46},"100638252","preoperative-immunonutrition-in-patients-with-bone-and-soft-tissue-sarcomas-100638252","NCT07609329","Preoperative Immunonutrition in Patients With Bone and Soft Tissue Sarcomas","Effect of Preoperative Immunomodulatory Nutritional Intervention on Postoperative Complications and Sarcopenia in Patients With Bone and Soft Tissue Sarcomas","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n* Adult patients aged 18 years or older.\n* Histologically confirmed bone sarcoma or soft tissue sarcoma.\n* Localized or oligometastatic disease.\n* Indicated for planned orthopedic tumor resection.\n* Preoperative interval allowing administration of the nutritional intervention for at least 7 days, with 14 days preferred when clinically feasible.\n* Ability to receive oral nutritional supplementation.\n* Signed informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Participants will be excluded if any of the following criteria are present:\n* Indication for urgent surgery.\n* Disseminated disease with more than five metastases.\n* Ongoing parenteral nutrition before study enrollment.\n* Inability to receive oral intake.\n* Severe hepatic failure.\n* Severe renal failure.",{"count":85,"type":23},[159],"NA","This study will evaluate whether a short nutritional intervention before surgery can improve recovery in patients with bone and soft tissue sarcomas.\n\nPatients with these tumors often have a higher risk of poor nutrition and loss of muscle mass. These problems may increase the risk of complications after major orthopedic surgery.\n\nParticipants will be randomly assigned to one of two groups. One group will receive a special oral nutritional supplement twice daily before surgery, in addition to standard care. The other group will receive standard care without the preoperative nutritional supplement.\n\nThe main aim of the study is to compare the rate of clinically relevant postoperative complications within 30 days after surgery. The study will also evaluate changes in muscle mass on CT scans, blood markers of nutrition and inflammation, nutritional risk, functional status, length of hospital stay, and tolerance of the nutritional supplement.",[162,163,164,30,165],"Bone Sarcoma","Soft Tissue Sarcoma","Sarcopenia","Postoperative Complications",[167,168,169,30,170,171,164],"Sarcoma","Bone sarcoma","Soft tissue sarcoma","Preoperative Nutrition","Immunonutrition","2026-05-19",{"date":174,"type":38},"2026-05-27",{"date":176,"type":38},"2026-04-01",{"date":178,"type":23},"2028-12-31",{"name":180,"class":45},"St. Anne's University Hospital Brno, Czech Republic",{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":24,"phases":190,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":46},"100636417","phase-2-nanocrystalline-megestrol-acetate-versus-placebo-for-anorexia-in-patients-with-unresectable-hepatocellular-carcinoma-receiving-tace-combined-with-targeted-and-immunotherapy-100636417","NCT07565415","Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy","A Multicenter, Randomized, Controlled Phase II Clinical Trial of Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy","Inclusion Criteria:\n\n* Patients with unresectable primary hepatocellular carcinoma (HCC) confirmed by imaging or histopathology\n* No previous receipt of immunotherapy and\u002For targeted drug therapy\n* Child-Pugh score ≤ 7\n* At least one measurable lesion per RECIST 1.1 criteria; lesions without prior radiotherapy, cryotherapy or other local treatment\n* Single intrahepatic lesion \\\u003C 10 cm, or fewer than 10 intrahepatic lesions with tumor burden \\\u003C 50%\n* Meet precachexia criteria: non-volitional weight loss ≤ 5% in 6 months, plus systemic inflammation (CRP \\> 5 mg\u002FL) or decreased appetite (FAACT-A\u002FCS-12 score ≤ 37 points)\n* Meet cachexia criteria: accompanied by decreased appetite or systemic inflammation, with either non-volitional weight loss \\> 5% in 6 months or BMI \\\u003C 18.5 kg\u002Fm² plus weight loss \\> 2%\n* Voluntarily participate and sign informed consent\n* Age ≥ 18 years, male or female\n* Able to swallow tablets normally\n* ECOG performance status 0 or 1\n* Life expectancy ≥ 12 weeks\n* Adequate major organ function without blood products or colony-stimulating factors within 14 days\n* Hematology: ANC ≥ 1.5×10⁹\u002FL, Hb ≥ 80 g\u002FL, PLT ≥ 50×10⁹\u002FL\n* Liver function: TBIL ≤ 1.5×ULN, AST\u002FALT ≤ 5.0×ULN, ALB ≥ 28 g\u002FL\n* Coagulation function: INR, PT or aPTT ≤ 1.5×ULN\n* Renal function: SCr ≤ 1.5×ULN or creatinine clearance ≥ 60 mL\u002Fmin\n* Urine protein ≤ 1+ or 24-hour urine protein \\\u003C 1.0 g\n* Cardiac function: LVEF ≥ 50%\n* Females of childbearing potential with negative pregnancy test within 3 days before first dosing\n* Fertile male and female patients agree to effective contraception from screening to 120 days after last study drug\n* HBV\u002FHCV infected patients receive stable antiviral therapy without drug interaction\n\nExclusion Criteria:\n\n* Active or untreated CNS metastases; inadequately controlled metastatic brain or leptomeningeal disease\n* Uncontrolled tumor-related pain\n* Thromboembolic disease, ascites or lower limb edema within 6 months\n* History of other malignancies within 5 years before randomization, except curable low-risk tumors\n* Unresolved adverse toxicities from prior antitumor therapy not recovered to ≤ Grade 1 (CTCAE v5.0), excluding alopecia\n* Pregnant, breastfeeding females or those planning pregnancy during the study\n* Any unstable medical, psychiatric or social condition that may interfere with study participation\n* Positive HIV infection\n* Major surgery within 28 days prior to randomization\n* Severe cardiovascular disease, myocardial infarction, unstable arrhythmia, angina or cerebrovascular events\n* Severe systemic infection within 4 weeks before dosing or active infection requiring systemic anti-infective treatment\n* Impaired gastrointestinal absorption, long-term tube feeding, parenteral nutrition or eating disorders\n* Concomitant use of other appetite-enhancing or weight-stimulating agents\n* Cushing's syndrome, adrenal or pituitary insufficiency, poorly controlled diabetes\n* Uncontrolled hypertension despite oral antihypertensive treatment\n* Esophagogastric varices, severe ulcers, gastrointestinal bleeding, obstruction, perforation or fistula within 6 months\n* Known hypersensitivity to any component of the investigational product\n* Any other condition considered inappropriate for enrollment by the investigator.",{"count":189,"type":23},88,[191],"PHASE2","Primary Objective: To evaluate the effect of nanocrystalline megestrol acetate versus placebo on body weight and appetite in patients with unresectable hepatocellular carcinoma receiving TACE combined with targeted and immunotherapy.Secondary Objectives: To evaluate the effect of nanocrystalline megestrol acetate versus placebo on quality of life, inflammatory markers, nutritional indicators, and psychological stress in patients with unresectable hepatocellular carcinoma receiving TACE combined with targeted and immunotherapy.Exploratory Objective: To explore the impact of nanocrystalline megestrol acetate versus placebo on survival benefit in patients with unresectable hepatocellular carcinoma receiving TACE combined with targeted and immunotherapy.",[194,195,89,30],"Hepatocellular Carcinoma (HCC)","Cachexia","2026-04-27",{"date":198,"type":38},"2026-05-04",{"date":200,"type":23},"2026-06-22",{"date":202,"type":23},"2027-09-01",{"name":204,"class":45},"Nanfang Hospital, Southern Medical University",{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":213,"targetDuration":214,"studyType":56,"phases":4,"briefSummary":215,"conditions":216,"keywords":218,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":46},"100542644","muscle-mass-via-ultrasound-in-cirrhosis-mmuscle-100542644","NCT06345547","Muscle Mass Via UltraSound in Cirrhosis (MMUSCLE)","Prospective Observational Cohort Survey to Assess the Prevalence and Development of Sarcopenia and the Correlation of Muscle Mass and Outcome in Patients With Cirrhosis by Skeletal Muscle Ultrasound.","MMUSCLE","Inclusion Criteria:\n\n* diagnosis of cirrhosis and follow-up in the University Hospital of Antwerp\n\nExclusion Criteria:\n\n* known patient will against participation in the study or against the measures applied in the study\n* a decision made prior to inclusion to stop further treatment of the patient within the next 24 hours\n* no complete remission of malignancy including hepatocellular carcinoma within the past 12 months",{"count":5,"type":23},"2 Years","The goal of this observational cohort study is to learn about loss of muscle mass and muscle strength (sarcopenia) in patients with cirrhosis. The main question\\[s\\] it aims to answer are:\n\n* what is the prevalence and development of sarcopenia in cirrhosis?\n* what is the role of malnutrition? Participants will\n\n  * undergo a muscle ultrasound of the lower and upper limb muscles\n  * handgrip strength will be measured\n  * malnutrition screening and assessment\n  * complete a questionnaire to assess quality of life",[164,217,30],"Cirrhosis",[219,220,221,222],"sarcopenia","cirrhosis","malnutrition","skeletal muscle ultrasound",{"date":224,"type":38},"2026-05-01",{"date":226,"type":38},"2024-05-06",{"date":228,"type":23},"2028-03-31",{"name":230,"class":45},"University Hospital, Antwerp",{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":24,"phases":242,"briefSummary":243,"conditions":244,"keywords":248,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":274},"100636088","nutrition-and-exercise-prehabilitation-in-patients-awaiting-liver-transplantation-100636088","NCT07561138","Nutrition and Exercise Prehabilitation in Patients Awaiting Liver Transplantation","Evaluation of Protein Distribution Optimization With Exercise Regimen on Nutritional Status, Body Composition and Functional Status in Patients Awaiting Liver Transplantation: The POWER-LT Randomized Clinical Trial","POWER-LT","Inclusion Criteria:\n\n* End-stage liver disease, diagnosed by transient elastography (FibroScan) or imaging-based evaluation with compatible clinical picture\n* Referred for liver transplantation and evaluated to have a high likelihood of being listed, according to primary hepatologist assessment, or already listed for liver transplantation\n* No prior formal dietary advice\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Estimated waiting time for liver transplantation \\\u003C 3 months\n* Estimated life expectancy \\\u003C 3 months\n* Chronic kidney disease requiring protein restriction\n* Exercise contraindicated (e.g., active or recent variceal bleeding, severe grade of hepatic encephalopathy, refractory ascites, etc.)\n* Unstable or severe psychiatric disorder\n* Pregnancy or lactation\n* Inability to provide written informed consent","70 Years",{"count":241,"type":23},90,[159],"This study aims to evaluate the effects of a diet with even protein distribution plus exercise (Group A) versus a diet with skewed protein distribution plus exercise (Group B) versus standard dietary and physical activity advice (Group C) on nutritional status, body composition and functional status in patients awaiting liver transplantation.",[245,246,247,30,164,88],"End-stage Liver Disease","Liver Cirrhosis","Liver Transplantation",[249,250,251,252,221,219,253,254,255,256,257,258,259,260,261,262,263,264,265],"liver disease","end-stage liver disease","liver cirrhosis","liver transplantation","frailty","diet","nutrition","nutrition therapy","protein","protein distribution","exercise","prehabilitation","nutritional status","body composition","functional status","physical performance","quality of life","2026-04-24",{"date":224,"type":38},{"date":269,"type":38},"2026-01-08",{"date":271,"type":23},"2029-07",{"name":273,"class":45},"Kalliopi Anna Poulia",2,{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":82,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":284,"conditions":285,"keywords":286,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":4},"100621805","3d-printed-extraoral-camera-for-standardized-dental-photography-100621805","NCT07375394","3D-Printed Extraoral Camera for Standardized Dental Photography","Evaluation of a 3D-Printed Extraoral Camera Assembly for Standardization of Dental Photography: Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Undergraduate dental students\n* Egyptian nationality\n* Both genders\n\nExclusion Criteria:\n\n* Postgraduate dental students\n* Incomplete questionnaires\n* Refusal to participate",{"count":283,"type":23},400,"This study evaluates whether a 3D-printed extraoral camera assembly can improve the reproducibility and dimensional consistency of dental photographs compared with conventional DSLR methods. By standardizing camera position, distance, and angle, the assembly provides a non-contact, operator-independent approach to ensure consistent image geometry, supporting more accurate clinical records, esthetic documentation, and digital analyses.",[30],[287,288],"undergraduate medical students","dental nutrition","2026-03-17",{"date":291,"type":38},"2026-03-19",{"date":293,"type":23},"2027-01-20",{"date":295,"type":23},"2027-01-30",{"name":297,"class":45},"Cairo University",{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":18,"minAge":306,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":309,"conditions":310,"keywords":314,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":46},"100558376","nutrition-and-clinical-outcomes-in-ibd-100558376","NCT06550310","Nutrition and Clinical Outcomes in IBD","Nutrition and Body Composition and Association With Clinical Outcomes in Inflammatory Bowel Disease","NUTRICO-IBD","Inclusion Criteria:\n\n* Patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis or IBD-U) starting a new advanced medical therapy\n* Patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis or IBD-U) undergoing an IBD-related surgery\n* Age \\>16\n* Patients able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Patients below the age of 16\n* Patients who cannot provide informed consent\n* Patients with a cardiac pacemaker or internal defibrillator\n* Patients with active cancer and other disorders associated with severe cachexia","16 Years",{"count":308,"type":23},300,"The goal of this observational study is to demonstrate that nutritional status and body composition have an impact on clinical outcomes in inflammatory bowel disease (IBD).\n\nThe main objectives are:\n\n1. To compare the detection rates of undernutrition between a range of nutritional screening tools, physiological measures and assessment tools amongst patients with different IBD phenotypes\n2. To correlate nutritional status, nutritional biomarkers and body composition with clinical outcomes in patients with IBD treated with advanced medical therapy or surgery\n3. To determine a potential relationship between radiological muscle mass measurements and clinical outcomes in patients with IBD treated with advanced medical therapy or surgery\n\nParticipants will undergo an assessment at pre-treatment baseline and then again at their scheduled follow-up. This is a non-interventional study and participants will not be required to have any invasive tests or hospital visits beyond that of standard clinical care.",[311,312,313,30,164],"Inflammatory Bowel Diseases","Crohn Disease","Ulcerative Colitis",[315,316,317,318,319,164,320,321],"Body composition","Nutritional status","Nutritional markers","Nutritional screening tools","Nutritional assessment","Radiological muscle mass","Inflammatory bowel disease","2026-02-17",{"date":324,"type":38},"2026-02-19",{"date":326,"type":38},"2024-10-24",{"date":328,"type":23},"2028-12",{"name":330,"class":45},"Barts & The London NHS Trust",{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":24,"phases":339,"briefSummary":340,"conditions":341,"keywords":344,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":357,"locationsCount":46},"100602567","incidence-of-depression-and-its-complications-after-surgical-site-infection---isodep-100602567","NCT07125196","Incidence of Depression and Its Complications After Surgical Site Infection - ISODEP.","ISODEP","Inclusion Criteria:\n\n* Patient \\>18 years old\n* Patient treated in infectiology for surgical site infection after orthopedic surgery of the limbs or spine:\n\n  * Prosthetic limb surgery\n  * Spinal surgery\n  * Traumatology: Osteosynthesis of peripheral limbs or spine\n\nExclusion Criteria:\n\n* Patient under guardianship or curatorship,\n* Pregnant, breastfeeding woman\n* Person deprived of liberty by judicial or administrative decision,\n* Person undergoing psychiatric treatment under duress requiring the consent of the legal representative.\n* Person unable to express their consent,\n* Person under legal protection,\n* Patient not affiliated to a social protection scheme.\n* Patient with a history of diagnosed depression, hospitalization for depressive disorders or taking mood-regulating treatments.\n* An initial BMI of less than \\\u003C 18.5, the existence a cancerous pathology, an ongoing inflammatory disease, a pathology responsible for chronic undernutrition",{"count":308,"type":23},[159],"Surgical-site infection (SSI) in orthopedic surgery is a serious and frequent complication with many consequences on the patient's quality of life. This study aims to describe the incidence of depression and its complications like malnutrition in patients followed for surgical site infection to allow their best management and prevention",[342,343,30],"Surgical Site Infections","Depression",[345,346,221,347,348,349,350],"surgical site infection","depression","orthopedic surgery","mood disorders","infection management","prospective study","2026-02-06",{"date":353,"type":38},"2026-02-09",{"date":355,"type":38},"2025-12-11",{"date":271,"type":23},{"name":358,"class":45},"University Hospital, Bordeaux",{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":24,"phases":368,"briefSummary":369,"conditions":370,"keywords":376,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":46},"100598506","nutritional-prehabilitation-to-improve-cancer-outcomes-n-pico-100598506","NCT07072377","Nutritional Prehabilitation to Improve Cancer Outcomes (N-PICO)","N-PICO","Inclusion Criteria:\n\n* Diagnosis of invasive cancer with plans to initiate chemo-, immune-, targeted-, or hormonal therapy for treatment of their malignancy, or within one month of starting treatment.\n* Age ≥ 18 years of age.\n* Patients must be able to read, write, and speak English as study material and virtual nutrition consultation calls are only available in English.\n* Patients receiving treatment at a participating ambulatory medical oncology site.\n* Willingness to have a remote nutritional consultation and complete questionnaires\u002Fsurveys.\n* Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.\n\nExclusion Criteria:\n\n* Diagnosis of acute leukemia (these patients generally receive predominantly inpatient care).\n* Diagnosis of head \\& neck cancer, esophageal cancer, gastric cancer, patients presenting with recognized cachexia or severe malnutrition, or patients with PEG tubes for enteral feeding.\n\nRationale: These patients would normally be referred for dietary consultation and may need ongoing clinical intervention from an on-site dietitian beyond the period of the proposed study",{"count":367,"type":23},240,[159],"Brief Summary\n\nThe goal of this clinical trial is to evaluate the acceptability and adherence of low- and high-intensity remote nutritional interventions for cancer patients in rural and urban areas, specifically focusing on those with invasive cancer who are about to start treatment. The main question\\[s\\] it aims to answer are:\n\nCan low- and high-intensity remote nutritional interventions improve adherence to cancer treatment and quality of life? What is the impact of nutritional support on treatment delays, unplanned healthcare utilization, and dietary modifications? Researchers will compare the low-intensity arm (initial nutritional consultation plus written materials) to the high-intensity arm (1-hour consultation, monthly follow-ups, and written materials) to see if higher intensity interventions lead to better outcomes in terms of adherence, quality of life, and healthcare utilization.\n\nParticipants will:\n\nReceive either a low- or high-intensity nutritional consultation. Complete surveys assessing quality of life, dietary habits, treatment delays, and unplanned healthcare use.\n\nBe asked to participate in monthly follow-up consultations (for the high-intensity group) to track progress and provide additional support.",[30,371,372,373,374,375],"Cancer-related Malnutrition","Quality of Life (QOL)","Nutritional Support","Nutritional Interventions","Rural Health",[377,378,379,380,381,382,383,384],"Cancer Nutrition Intervention","Malnutrition in Cancer Patients","Nutritional Support for Cancer","Prehabilitation Program for Cancer","Rural Cancer Nutrition","Quality of Life and Cancer Nutrition","Remote Nutritional Consultations","Cancer Treatment Outcomes and Nutrition","2026-02-02",{"date":387,"type":38},"2026-02-05",{"date":389,"type":38},"2025-09-10",{"date":391,"type":23},"2028-09",{"name":393,"class":45},"University of Vermont Medical Center",{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":404,"conditions":405,"keywords":409,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":427},"100612375","nutritional-management-of-the-patient-with-type-2-diabetes-at-nutritional-risk-or-with-malnutrition-in-clinical-practice-100612375","NCT07252765","Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice","Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice. STARLIGHT Study","STARLIGHT","Inclusion Criteria:\n\n* Adult patients diagnosed with type 2 diabetes (T2D) or drug-induced diabetes\n* Patients at nutritional risk according to MUST or presenting malnutrition according to GLIM criteria.\n* Patients requiring a diabetes-specific oral nutritional supplement (ONS) that is high-calorie, high-protein, and contains soluble fiber in real-world clinical practice, and who have been prescribed such a supplement within the previous 7 days.\n* Patients able to provide informed consent and complete the study questionnaires.\n\nExclusion Criteria:\n\n* Patients participating in other studies or clinical trials related to malnutrition, or who, in the investigator's opinion, may alter the course of the study.\n* Patients currently receiving or expected to receive other types of nutritional interventions involving supplements (oral or otherwise) or non-conventional feeding methods (e.g., feeding tubes).\n* Patients with a history of metabolic\u002Fendocrine diseases (other than diabetes) or any other condition causing liver or kidney failure, defined as ALT \\> 3x ULN or eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m², and according to the investigator's judgment.\n* Patients expected to undergo any surgical intervention or require hospitalization due to a condition unrelated to the study during the study period.\n* Patients with other conditions that, in the investigator's opinion, may interfere with adherence to the intervention or with study procedures.",{"count":403,"type":23},334,"The objective of this observational study is to characterize the patient profile and nutritional treatment patterns of individuals with type 2 diabetes (T2D) or drug-induced diabetes who present with malnutrition, or are at risk of it, and who are prescribed a diabetes-specific oral nutritional supplement (ONS) that is high in calories and protein and contains soluble fiber.\n\nParticipants will complete a series of questionnaires during visits 1 and 3.",[406,30,407,408],"Type 2 Diabetes Mellitus (T2DM)","Malnourishment","Drug-Induced Diabetes",[410,411,412,413,414,415,407,30,416],"Metabolic control","Disease - realted malnutrition","Diabetes-specific formula","T2D","Oral nutritional supplementation","Type 2 Diabetes Mellitus","Drug-induced diabetes","2026-01-26",{"date":419,"type":38},"2026-01-28",{"date":421,"type":38},"2025-11-20",{"date":423,"type":23},"2026-10",{"name":425,"class":426},"Outcomes'10","NETWORK",12,{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":434,"eligibilityCriteria":435,"healthyVolunteers":82,"sex":18,"minAge":19,"maxAge":436,"enrollmentInfo":437,"targetDuration":4,"studyType":24,"phases":438,"briefSummary":439,"conditions":440,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":46},"100524931","breath-analysis--malnutrition-100524931","NCT06115148","Breath Analysis & Malnutrition","Breath Ammonia as a Malnutrition Screening Tool","BAM-S","Inclusion Criteria:\n\n1. Age: 18-95 years\n2. Malnutrition group (Cross-sectional study only); not involved in intervention: Diagnosed with malnutrition (verified in medical history)\n\nExclusion Criteria:\n\n1. Chronic kidney, liver or pulmonary disease\n2. Anabolic steroid use other than testosterone (e.g., oxandrolone)\n3. Patients judged unsuitable for enrollment by the study medical investigator\n4. Pregnant women or women who are nursing\n5. Unable or unwilling to consume study beverages or fast for 24 hours each arm","95 Years",{"count":427,"type":23},[159],"The purpose of this research study is to understand how breath is related to nutritional status. The procedures involved in this study include blood and breath sampling, questionnaires about health history, medications, nutritional status and diet, and a physical examination. Breath markers will be compared between individuals with and without malnutrition and be compared to indicators of malnutrition. Some individuals will undergo an interventional study involving 2 days of consuming study beverages and fasting along with providing additional breath samples to see if the breath changes in response to short-term changes in nutritional status.",[30],"2026-01-16",{"date":443,"type":38},"2026-01-21",{"date":445,"type":38},"2023-08-17",{"date":447,"type":23},"2026-12-30",{"name":449,"class":45},"Pennington Biomedical Research Center",{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":457,"enrollmentInfo":458,"targetDuration":4,"studyType":24,"phases":459,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":274},"100509744","nutritional-support-on-outcomes-and-cost-effectiveness-for-patients-at-risk-100509744","NCT05917418","Nutritional Support on Outcomes and Cost-effectiveness for Patients at Risk","Impact of Nutritional Support on Outcome,Cost\u002FEffectiveness for Patient at Risk","Inclusion Criteria:\n\n* patients be in hospital overnight\n* diagnoses according to the protocol of cohort study for cost effectiveness\n\nExclusion Criteria:\n\n* patients admitting from emergency department\n* patients who undergone operation before second morning of hospitalization\n* patients who dose not give Informed Consents","90 Years",{"count":283,"type":23},[159],"The impact of nutritional support for the patients at nutritional risk on clinical outcomes and cost-effectiveness.",[30],"2026-01-07",{"date":464,"type":38},"2026-01-09",{"date":466,"type":23},"2026-12-01",{"date":468,"type":23},"2040-01-30",{"name":470,"class":45},"Peking Union Medical College",{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":477,"enrollmentInfo":478,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":480,"conditions":481,"keywords":483,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":55},"100079403","nutrition-support-on-outcomes-and-cost-effectiveness-for-patients-at-risk-100079403","NCT00289380","Nutrition Support on Outcomes and Cost-effectiveness for Patients at Risk","1. Prevalence of Nutritional Risk-undernutrition-support in China-Euro-USA. 2. Impact of Nutrition Support on Outcome for Patient at Risk. 3. Impact of Nutrition Support on Outcome,Cost\u002FEffectiveness for Patient at Risk.","80 Years",{"count":479,"type":23},2000,"1. The aim of this large scale study to survey the prevalence of nutritional risk and malnutrition in China,Europe and USA.\n2. The impact of nutritional support for the patients at nutritional risk on clinical outcomes and cost-effectiveness\n\nAlready get the approval by Ethics Committee of Peking Union medical college and Johns Hopkins Hospital.",[30,482],"Nutritional Risk",[484,30,485,486,487,488,489,490,491],"Nutritional Risk Screening(NRS)","Overweight","Obesity","Clinical nutritional support","Clinical outcome","Cost effectiveness","Complication","Infective complications",{"date":464,"type":38},{"date":494,"type":4},"2005-01",{"date":496,"type":23},"2040-01",{"name":470,"class":45},{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":24,"phases":508,"briefSummary":509,"conditions":510,"keywords":513,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":46},"100526979","early-nutritional-intervention-in-patients-with-cancer-100526979","NCT06141785","Early Nutritional Intervention in Patients With Cancer","Early Nutritional Intervention to Prevent Malnutrition in Patients With Cancer Receiving Palliative Chemotherapy in an Outpatient Setting","NICOS","Inclusion Criteria:\n\n* patients who are newly diagnosed with lung, colorectal, ovarian, or pancreatic cancer.\n* patients treated with first-line palliative chemotherapy\n* patients who are Danish speaking\n* patients ≥18 years of age\n* patients who are cognitive well-functioning\n\nExclusion Criteria:\n\n* Patients not using electronic mail\n* patients with dementia\n* patients not able to comply with the study protocol",{"count":507,"type":23},200,[159],"The goal of this intervention study is to study the effect of nutritional interventions in patients with cancer receiving palliative chemotherapy. The main question it aims to answer is: Does early nutritional interventions affect body weight, quality of life, survival, muscle mass, performance status, physical function, nutritional risk and treatment tolerance in patients with cancer receiving palliative chemotherapy? Researchers will compare patients receiving the intervention to a historical control cohort following current clinical practice.",[511,512,30],"Nutritional Intervention","Cancer",[514,515,512,30,516],"Nutritional interventions","Dietetics","Nutrition","2025-12-17",{"date":519,"type":38},"2025-12-24",{"date":521,"type":38},"2024-06-01",{"date":523,"type":23},"2027-01-29",{"name":525,"class":45},"Gødstrup Hospital",{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":83,"enrollmentInfo":533,"targetDuration":4,"studyType":24,"phases":535,"briefSummary":536,"conditions":537,"keywords":541,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":548,"completionDateStruct":549,"leadSponsor":551,"locationsCount":46},"100615203","tailored-stapled-sadi-s-initial-report-and-preliminary-results-100615203","NCT07289555","Tailored Stapled SADI-S: Initial Report and Preliminary Results","Tailored Stapled Single Anastomosis Duodeno-ileal Bypass With Sleeve Gastrectomy (SADI-S): Initial Report and Preliminary Results","Inclusion Criteria:\n\n* Adults aged 18-65 years.\n* BMI ≥35 kg\u002Fm² or BMI ≥30 kg\u002Fm² with obesity-related comorbidities such as type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, obstructive sleep apnea, or non-alcoholic fatty liver disease.\n* Willingness to adhere to follow-up visits and testing.\n* Indicated for revisional SADI-S post sleeve gastrectomy for inadequate weight loss or weight regain.\n\nExclusion Criteria:\n\n* Severe uncontrolled medical or psychiatric conditions preventing adherence to the protocol.\n* Known short bowel syndrome or previous extensive bowel resections or intraoperative finding of extensive bowel adhesions.",{"count":534,"type":23},40,[159],"Obesity is a serious health problem worldwide and can lead to many diseases such as diabetes, high blood pressure, heart disease, and sleep apnea. When lifestyle changes and medications are not enough, metabolic and bariatric surgery (MBS) is currently the most effective and long-lasting treatment option.\n\nThis study focuses on one of the newer types of bariatric surgery called Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S). This procedure combines two parts:\n\nSleeve gastrectomy, which reduces the size of the stomach so the patient feels full after eating a small amount.\n\nDuodeno-ileal bypass, which shortens the path food takes through the small intestine to reduce calorie absorption.\n\nOur hospital's surgical team is studying a tailored version of this operation, where the length of the bypassed intestine is adjusted to each patient's anatomy. We believe this personalized approach may improve weight loss results while lowering the risk of vitamin and nutrient deficiencies.\n\nThe study will include 40 adult patients with obesity who are undergoing SADI-S surgery, either as their first weight loss operation or as a revision surgery after an earlier sleeve gastrectomy. During the operation, surgeons will measure the total length of each patient's small intestine and use a formula to decide how much of it should be bypassed. The duodeno-ileal connection will be made using a stapled technique, which is expected to be safe and efficient.\n\nAfter surgery, patients will be followed regularly at 1, 3, 6, 9, and 12 months, and then once per year. At each visit, the study team will monitor weight loss, body mass index (BMI), resolution of diabetes and other obesity-related conditions, nutritional status (including vitamins and minerals), and any side effects such as diarrhea, reflux, or nutritional problems.\n\nThe goal of this study is to learn whether this tailored SADI-S technique can provide strong, sustained weight loss and health improvement with fewer long-term complications. The results will help improve surgical planning for future patients by showing whether measuring and customizing the bypass length is safer and more effective than using a fixed length.\n\nAll data collected will be kept confidential. Patients' participation in the study will not change their regular care or follow-up, and they can withdraw at any time without affecting their treatment.",[538,539,30,540],"Morbid Obesity","Bariatric Surgery","Comorbidities",[542,543,544,545,316],"SADI-S","Bariatric surgery","Limb length tailoring","Weight loss outcomes","2025-12-04",{"date":517,"type":38},{"date":521,"type":38},{"date":550,"type":23},"2026-12-31",{"name":552,"class":553},"El-Sahel Teaching Hospital","OTHER_GOV",{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":18,"minAge":562,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":565,"conditions":566,"keywords":569,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":582,"locationsCount":46},"100613169","elderly-health-profile-in-a-rural-village-of-assiut-100613169","NCT07263087","Elderly Health Profile in a Rural Village of Assiut","Health Profile of the Elderly Population in a Rural Area of Assiut Governorate: A Community-Based Cross-Sectional Study","RURAL-AGE","Inclusion Criteria:\n\n* Age ≥ 60 years\n* Resident in the selected rural village in Assiut\n* Able to communicate and respond to interview questions\n* Provides informed consent to participate\n\nExclusion Criteria:\n\n* Bedridden or severely ill preventing participation\n* Severe cognitive impairment preventing interview\n* Refusal to participate","60 Years",{"count":564,"type":23},330,"This study aims to assess the health, nutrition, functional status, and quality of life of older adults living in Al-Boura village in Assiut, Egypt. It is an observational, community-based study that includes adults aged 60 years and above. Participants will complete interviews covering medical history, lifestyle behaviors, functional ability, mental health, nutrition, and quality of life. Physical measurements such as weight, height, blood pressure, and simple clinical assessments will also be performed. The goal of the study is to describe the current health needs of the elderly population and identify risk factors for chronic diseases, malnutrition, and functional decline. The results will help guide local health services and future elderly-care programs in Upper Egypt. No treatments or interventions will be given as part of this study.",[567,30,88,568],"Chronic Diseases in Older Adults","Functional Decline Geriatric Health",[570,571,572,573,574,375,575],"Elderly Health","Geriatric Assessment","Nutrition in Older Adults","Functional Status","Chronic Disease Burden","Upper Egypt","2025-12-03",{"date":578,"type":38},"2025-12-05",{"date":580,"type":23},"2026-01",{"date":42,"type":23},{"name":583,"class":45},"Assiut University",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":18,"minAge":591,"maxAge":592,"enrollmentInfo":593,"targetDuration":4,"studyType":24,"phases":594,"briefSummary":596,"conditions":597,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":601,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":605,"locationsCount":607},"100519909","phase-4-safety-study-of-smoflipid-to-evaluate-the-risk-of-developing-efad-andor-pnac-in-pediatric-and-adult-patients-100519909","NCT06049680","Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and\u002For PNAC in Pediatric and Adult Patients","A Single-arm Open-label Safety Study of SMOFlipid to Evaluate the Risk of Developing Essential Fatty Acid Deficiency (EFAD) and\u002For Parenteral Nutrition-associated Cholestasis (PNAC) in Pediatric Patients 1 Month to 17 Years of Age and in Adult Patients, Who Are Anticipated to Need 8 Weeks or Longer of Parenteral Nutrition Treatment","Age Limits: and Adults\n\nInclusion Criteria:\n\n1. Male or female patients, at least 1 month of age.\n2. Patients who require PN for at least 5 days\u002Fweek.\n3. Patients who receive 80% or more of their total energy requirements as PN at enrollment and who are expected to receive 80% or more of their total energy requirements as PN for at least 56 days.\n4. Written informed consent. In case of pediatric patients, informed consent must be obtained from parent(s) or legal representatives. If possible, the assent of the pediatric patient must also be obtained (according to local law).\n\nExclusion Criteria:\n\n1. Use of any other lipid injectable emulsion than SMOFlipid within 6 months prior to study participation\n2. Known hypersensitivity to fish, egg, soybean, or peanut proteins, or to any of the active ingredients or excipients of SMOFlipid.\n3. Hyperlipidemia or disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentration \\>250 mg\u002FdL in infants or \\>400 mg\u002FdL in older pediatric and adult patients).\n4. Inborn errors of amino acid metabolism.\n5. Cardiopulmonary instability (including pulmonary edema, cardiac insufficiency, myocardial infarction, acidosis and hemodynamic instability requiring significant vasopressor support).\n6. Hemophagocytic syndrome.\n7. Liver enzymes (either AST, or ALT, or GGT) exceeding 2 x upper limit of normal range\n8. Direct bilirubin exceeding 2 x upper limit of normal range\n9. INR exceeding 2 x upper limit of normal range and patient not receiving oral anticoagulants.\n10. Any known hepatic condition outside of IFALD that will increase direct bilirubin ≥2.0 mg\u002FdL.\n11. Clinically significant abnormal levels of any serum electrolyte (sodium, potassium, magnesium, calcium, chloride, phosphate).\n12. Active bloodstream infection demonstrated by positive blood culture at screening.\n13. Severe renal failure (eGFR \\\u003C15 ml\u002Fmin per 1.73 m2) including patients on renal replacement therapy.\n14. Abnormal blood pH, oxygen saturation, or carbon dioxide.\n15. Pregnancy or lactation.\n16. Participation in another interventional clinical study.\n17. Unlikely to survive longer than 56 days.","1 Month","17 Years",{"count":85,"type":23},[595],"PHASE4","Evaluate the risk of developing EFAD and\u002For PNAC in adult and pediatric patients 1 month of age and older, who are anticipated to need 8 weeks or longer of parenteral nutrition treatment with SMOFlipid.",[598,30,599,600],"Malnutrition, Child","Essential Fatty Acid Deficiency (EFAD)","Parenteral Nutrition Associated Cholestasis",{"date":546,"type":38},{"date":603,"type":38},"2024-10-28",{"date":42,"type":23},{"name":606,"class":149},"Fresenius Kabi",5,{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":18,"minAge":616,"maxAge":4,"enrollmentInfo":617,"targetDuration":4,"studyType":24,"phases":618,"briefSummary":619,"conditions":620,"keywords":621,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":46},"100570393","implementation-of-nutritional-efforts-on-discharged-older-patients-100570393","NCT06706661","Implementation of Nutritional Efforts on Discharged Older Patients","Implementation of Nutritional Treatment to Older Patients Discharged With the Liaison Team","KMH2","Inclusion Criteria:\n\nPrescription of the Liaison team At nutritional risk according to NRS2002 Age 50+ Can read, hear and understand Danish or English Cognitive able to participate in the study, based on whether they are informed in time, place and own data\n\nExclusion Criteria:\n\nReceives enteral or parenteral nutrition Following a special diet including texture modified food and drinks Short life expectancy Not deemed eligible by the project staff","50 Years",{"count":479,"type":23},[159],"The aim of the study is to implement a nutritional treatment when discharging older patients at risk of malnutrition.\n\nData collected in the study will include an assessment of whether a combination of nutritional treatment and a liaison team reduces the risk of readmissions and mortality, improves nutritional status, physical function and quality of life",[30],[622,623,221,624,265,625,626,627,628],"food","dietician","nutrition risk","muscle strength","readmissions","mortality","multimodal","2025-11-27",{"date":546,"type":38},{"date":632,"type":38},"2025-01-06",{"date":634,"type":23},"2030-12-31",{"name":636,"class":45},"Herlev and Gentofte Hospital",{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":4,"eligibilityCriteria":643,"healthyVolunteers":12,"sex":18,"minAge":239,"maxAge":4,"enrollmentInfo":644,"targetDuration":4,"studyType":24,"phases":646,"briefSummary":647,"conditions":648,"keywords":649,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":655,"completionDateStruct":657,"leadSponsor":658,"locationsCount":46},"100579577","pancrelipase-with-nutritional-supplement-in-patients-at-risk-of-malnutrition-effort-enzo-100579577","NCT06826105","Pancrelipase With Nutritional Supplement in Patients at Risk of Malnutrition (EFFORT-ENZO)","Effect of Low Dose Pancrelipase With an Oral Nutritional Supplement to Improve Nutrient Bioavailability in Patients at Increased Risk of Malnutrition","Inclusion Criteria:\n\n* Informed Consent as documented by signature\n* Male or female 70 years of age or older\n* Hospitalized at site\n* Nutrition Risk Screening 2002 (NRS-2002) ≥ 3\n* eGFR ≥ 30 mL\u002Fmin\u002F1.73 m2 (EPI-CKD) based on medical history (no older than 6 months)\n* Ability to eat orally\n\nExclusion Criteria:\n\n* Patients with acute cardiovascular event ≤ 2 days\n* Patients with terminal conditions\n* Patients diagnosed with pancreatic exocrine insufficiency (EPI) treated with pancreatic enzyme replacement therapy (PERT)\n* Patients having a planned transplant or new-onset dialysis in the next 6 months.\n* Patients having a colectomy, resection of the small intestine or cholecystectomy\n* Known hypersensitivity to any of the substances or excipients of the ONS or the medicinal product",{"count":645,"type":23},20,[159],"This study investigates if pancreatic enzymes in combination with oral nutritional supplement can improve nutrient bioavailability in older people with malnutrition or at risk of malnutrition.",[30],[650,651],"Pancrelipase","Oral nutritional supplements","2025-09-24",{"date":654,"type":38},"2025-09-30",{"date":656,"type":38},"2025-09-22",{"date":580,"type":23},{"name":659,"class":45},"Philipp Schuetz",{"id":661,"slug":662,"hasResults":12,"nctId":663,"briefTitle":664,"officialTitle":665,"acronym":666,"eligibilityCriteria":667,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":668,"enrollmentInfo":669,"targetDuration":671,"studyType":56,"phases":4,"briefSummary":672,"conditions":673,"keywords":675,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":682,"lastUpdatePostDateStruct":683,"startDateStruct":685,"completionDateStruct":687,"leadSponsor":689,"locationsCount":46},"100605452","body-composition-assessment-and-monitoring-in-inflammatory-bowel-disease-100605452","NCT07162701","Body Composition Assessment and Monitoring in Inflammatory Bowel Disease","Body Composition Assessment and Monitoring With Bioelectrical Impedance Analysis to Predict Medical Therapy Efficacy in Inflammatory Bowel Disease (the BAMBIE Study)","BAMBIE","Inclusion Criteria:\n\n* Any sex.\n* Age between 18 and 64 years.\n* Patients with a definitive diagnosis (\\>3 months) of Crohn's disease or ulcerative colitis, according to European Crohn's and Colitis Organization criteria.\n* Moderate-to-severe disease luminal activity, with an indication for biologic or JAKi therapy for the induction of clinical remission.\n\nExclusion Criteria:\n\n* Unclassified IBD.\n* History of intestinal resection for IBD, with the exception of ileocecal resection.\n* Short bowel syndrome.\n* Indication for medical treatment due to postsurgical recurrence.\n* Active perianal disease.\n* Indication for medical treatment due to intestinal stricture.\n* Previous participation in a clinical trial involving medication for IBD treatment.\n* Engaging in vigorous physical activity (\\>6 Metabolic Equivalent of Task, METs) for more than 3 days per week.\n* Habitual alcohol consumption (\\>1 standard drink unit\u002Fday).\n* Diabetes mellitus with inadequate glycemic control.\n* Chronic use of diuretics.\n* Chronic kidney disease on dialysis.\n* Presence of dependent edema and\u002For ascites.\n* Cardiac pacemaker bearers.\n* Pregnant or lactating women.\n* Inability to sign informed consent.","64 Years",{"count":670,"type":23},48,"12 Months","This is a single-center, prospective observational study aiming to describe changes in body composition (specifically, percentage of lean mass and phase angle) in patients with active inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease.\n\nThe study will recruit patients with a confirmed IBD diagnosis who are starting biologic therapy or Janus kinase inhibitors (JAKi) to induce clinical remission. Body composition will be assessed using bioelectrical impedance analysis (BIA) at baseline (time 0), 24 weeks, and 52 weeks after starting medication. Clinical disease activity, endoscopic findings, and laboratory data will also be collected at various time points if available.\n\nThe study has a total duration of 36 months, including a 12-18 month patient inclusion period and a 12-month follow-up. Patients will provide informed consent, and all treatment decisions will follow standard clinical practice, as this is a non-interventional observational study.",[674,30],"Body Composition Changes",[221,676,677,678,679,680,681],"IBD","BIA","composition","body","Crohn","colitis","2025-09-08",{"date":684,"type":38},"2025-09-09",{"date":686,"type":38},"2025-07-15",{"date":688,"type":23},"2028-07-15",{"name":690,"class":45},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":692,"slug":693,"hasResults":12,"nctId":694,"briefTitle":695,"officialTitle":696,"acronym":4,"eligibilityCriteria":697,"healthyVolunteers":12,"sex":18,"minAge":698,"maxAge":592,"enrollmentInfo":699,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":700,"conditions":701,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":705,"lastUpdatePostDateStruct":706,"startDateStruct":708,"completionDateStruct":710,"leadSponsor":712,"locationsCount":713},"100537204","safety-study-to-evaluate-the-occurrence-of-efad-in-pediatric-patients-with-pnac-who-require-more-than-eight-weeks-of-omegaven-treatment-100537204","NCT06274788","Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment","Title: A Single-arm, Open-label, Prospective, Multicenter Safety Study to Evaluate the Occurrence of Essential Fatty Acid Deficiency (EFAD) in Pediatric Patients With Parenteral Nutrition-associated Cholestasis (PNAC) Who Require More Than Eight Weeks of Omegaven Treatment","Inclusion Criteria:\n\n1. Patient's parent(s) or legal guardian(s) has provided a signed and dated Informed Consent Form (ICF).\n2. Pediatric patient (\\\u003C18 years) has been diagnosed with PNAC, defined as direct or conjugated bilirubin (DBil) ≥ 2.0 mg\u002FdL with no other known cause of liver dysfunction at the time of enrollment and is expected to require Omegaven treatment for at least eight weeks.\n3. Patient has oral or enteral feeding intolerance or at least one gastrointestinal disorder requiring PN.\n\nExclusion Criteria:\n\n1. Patient has received Omegaven within four weeks before inclusion in the study\n2. Patient has any other known cause of chronic liver disease such as hepatitis C, cystic fibrosis, biliary atresia, alpha-1-antitrypsin deficiency, passive hepatic congestion due to heart failure, etc.\n3. Patient has known cirrhosis (liver biopsy is not required under this protocol).\n4. Patient has been previously diagnosed with, or has prior evidence of, portal vein thrombosis.\n5. Patient has previously received a liver-only or liver-inclusive transplant.\n6. Patient has hemodynamic instability due to any major cardiac anomaly.\n7. Patient has a major life-threatening disease (e.g., sepsis requiring high-dose vasopressors, acute respiratory distress syndrome, veno-occlusive disease, cancer).\n8. Patient has multi-organ failure, septic shock, hypotension requiring pressor therapy, persistent pulmonary hypertension requiring inhaled nitric oxides, or requires extracorporeal membrane oxygenation (ECMO) or similar intervention.\n9. Patient has renal failure and requires renal replacement therapy.\n10. Patient has a severe hemorrhagic disorder.\n11. Patient has severe hyperlipidemia or a severe disorder of lipid metabolism characterized by hypertriglyceridemia (i.e., serum triglyceride level \\> 1,000 mg\u002FdL).\n12. Patient has a record of EFAD before inclusion in the study\n13. Patient has been diagnosed with or is suspected to have an inborn error of metabolism.\n14. Patient has a known hypersensitivity to fish or egg protein or to any of the active ingredients or excipients of Omegaven.\n15. Patient is subject to treatment limitation.\n16. Patient is enrolled in any other study with an investigational medicinal product during the course of the current study.","1 Day",{"count":534,"type":23},"This study will demonstrate safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population",[702,703,30,704],"Parenteral Nutrition Associated Liver Disease (PNALD)","Essential Fatty Acid Deficiency","Pediatric ALL","2025-08-28",{"date":707,"type":38},"2025-09-05",{"date":709,"type":38},"2024-12-15",{"date":711,"type":23},"2027-03-01",{"name":606,"class":149},10]